ISSN: 1734-1922
Archives of Medical Science Special Issues
Current issue Archive Archives of Medical Science
Search
3/2007
 
Share:
Send email
Share:
abstract:

Invited review
Anti-inflammatory effects of trimetazidine in patients with ischemic heart disease

Pericle Di Napoli
,
Antonio Barsotti

Online publish date: 2008/01/10
View full text Get citation
 
Recent studies have demonstrated that alterations in cardiac metabolism occur in ischemic heart disease and heart failure. This suggests that there is an increased utilization of non-carbohydrate substrates for energy production with a resultant reduction in the efficiency of myocardial oxygen consumption. A direct approach to modifying cardiac energy metabolism could involve altering substrate utilization. Trimetazidine, which acts by selectively inhibiting mitochondrial 3-ketoacyl-coenzyme A thiolase, (an enzyme involved in b-oxidation) is an antianginal drug that shifts the preference for energy substrate away from fatty acid metabolism and towards glucose metabolism. It has a reduces ischemia-reperfusion damage and left ventricular function by reducing cell damage, tissue inflammation and left ventricle remodeling. Recent research has demonstrated that the anti-inflammatory action of trimetazidine reduces long-term mortality in patient with ischemic cardiomyopathy.
keywords:

trimetazidine, coronary artery disease, inflammation, reperfusion injury, heart metabolism
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.